EGFR and neoplasm: Chemotherapy regimens containing oxaliplatin or irinotecan, along with anti-EGFR for tumors with wild-type RAS/BRAF or anti-VEGF for tumors with RAS/BRAF mutations, were successful in enhancing the rate of tumor removal and improving overall survival [46].